The pioneer test subject for Neuralink, Elon Musk’s startup focused on
brain chip implants, has encountered an issue merely a few weeks post-insertion.
In a
published blog entry, the corporation disclosed that several of the chip's connecting threads withdrew from the subject Noland Arbaugh's brain, impeding the implant's data transmission speeds and efficacy. The details surrounding the incident were scant, including the precise cause of the thread detachment. Nevertheless, the corporation managed to heighten the implant's sensitivity, thereby enhancing its performance.
Arbaugh, the inaugural human recipient of Neuralink's technology, has lived with quadriplegia since a diving mishap in 2016. He
received the chip implant in January as part of the PRIME Study, an acronym for Precise Robotically Implanted Brain-Computer Interface.
The objective is to scrutinize the safety of both the implant and surgical robotics and to evaluate the functionality of the device, as outlined in a 2023
blog post soliciting trial participants.
Participants in the trial undergo surgical placement of chips in the brain region governing motor intention. These chips, installed via robotic assistance, capture and transmit brain signals to an application, initially aiming to enable individuals to manipulate a computer cursor or keyboard solely through thought, as previously elucidated by Neuralink.
Approximately a month post-operation, Musk announced Arbaugh's ability to manipulate a computer mouse using his brain post-implantation.
Ultimately,
Neuralink aspires to leverage implants for interfacing human brains with computers to aid, for instance, individuals with paralysis in controlling smartphones or computers, or to restore vision to the blind. Analogous to existing brain-computer interfaces, the corporation's implant would gather brain-emitted electrical signals and interpret them as commands.
Previously, Musk mentioned that the company's inaugural offering would be dubbed Telepathy, elaborating that the initial recipients would be individuals deprived of limb functionality.
"Imagine if Stephen Hawking could communicate more swiftly than a professional typist or auctioneer. That is the objective," Musk articulated.
Nevertheless, widespread consumer access to the technology remains distant. Before Neuralink's brain implants can reach the broader market, they necessitate comprehensive regulatory endorsement.
Neuralink has already secured clearance from the Food and Drug Administration for trials and has notified the agency of this recent issue, as
reported initially by the Wall Street Journal.
